Evidence map›Paper›PMID 40630387›Full record

ArticleERJ open research2025

Protocol for the INFORM ASTHMA Trial: budesonide-formoterol reliever in adults with asthma on maintenance inhaled corticosteroid.

Jonathan Noble, Orlagh Bean, Pepa Bruce, Melissa Black, Ross Sayers, Ryan Cullen, Bianca Black, Mark Holliday, Louis Kirton, Blake Perry and 4 more

Abstract read
In one paragraph

Article in ERJ open research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Jonathan NobleMedical Research Institute of New Zealand, Wellington, New Zealand.ORCID https://orcid.org/0009-0001-7620-3125
Orlagh BeanMedical Research Institute of New Zealand, Wellington, New Zealand.
Pepa BruceMedical Research Institute of New Zealand, Wellington, New Zealand.ORCID https://orcid.org/0000-0002-0317-0641
Melissa BlackMedical Research Institute of New Zealand, Wellington, New Zealand.ORCID https://orcid.org/0000-0002-5340-643X
Ross SayersMedical Research Institute of New Zealand, Wellington, New Zealand.ORCID https://orcid.org/0000-0001-8780-9109
Ryan CullenMedical Research Institute of New Zealand, Wellington, New Zealand.ORCID https://orcid.org/0009-0003-5864-7915
Bianca BlackMedical Research Institute of New Zealand, Wellington, New Zealand.ORCID https://orcid.org/0000-0002-0559-5635
Mark HollidayMedical Research Institute of New Zealand, Wellington, New Zealand.
Louis KirtonMedical Research Institute of New Zealand, Wellington, New Zealand.ORCID https://orcid.org/0000-0001-6941-1615
Blake PerryMedical Research Institute of New Zealand, Wellington, New Zealand.ORCID https://orcid.org/0000-0003-4197-519X
Allie EathorneMedical Research Institute of New Zealand, Wellington, New Zealand.
Ian PavordRespiratory Medicine Unit, Nuffield Department of Medicine and NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK.
Mark WeatherallUniversity of Otago Wellington, Wellington, New Zealand.
Richard BeasleyMedical Research Institute of New Zealand, Wellington, New Zealand.ORCID https://orcid.org/0000-0003-0337-406X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: International asthma guidelines recommend inhaled corticosteroid (ICS)/formoterol in preference to short-acting β Objective: The objective of the present study is to determine the anti-inflammatory effect, efficacy and safety of budesonide-formoterol reliever therapy Methods: A 26-week, open-label, parallel-group, 2-arm, phase IV, two-sided superiority RCT will recruit 180 adults aged 16-75 years with a clinical diagnosis of asthma using reliever only therapy, or SABA reliever therapy with maintenance ICS at baseline, and with baseline Conclusion: This will be the first RCT comparing ICS/formoterol

Identifiers

PMID40630387
PMCPMC12230752

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.